当前位置: X-MOL 学术Vet. Comp. Oncol. › 论文详情
Our official English website, www.x-mol.net, welcomes your feedback! (Note: you will need to create a separate account there.)
Retrospective outcome evaluation for dogs with surgically excised, solitary Kiupel high-grade, cutaneous mast cell tumours.
Veterinary and Comparative Oncology ( IF 2.3 ) Pub Date : 2020-01-14 , DOI: 10.1111/vco.12565
Antony S Moore 1 , Angela E Frimberger 1 , David Taylor 2 , Neill Sullivan 3
Affiliation  

Published outcomes for dogs with specifically high‐grade mast cell tumours (MCTs), controlled for clinical stage, are few. Clinical outcomes for 49 dogs with Kiupel high‐grade, clinical stage I, cutaneous MCTs were evaluated. Median survival time (MST) was 1046 days; 1 and 2‐year survival rates were 79.3% and 72.9%, respectively. At study end 24 dogs had died, 23 dogs were alive (median follow‐up 980 days) and 2 dogs were lost to follow‐up. Death was considered MCT‐related in 14 of 20 dogs with a known cause of death. Local tumour recurrence developed in nine dogs (18.4%); regional lymph node metastasis occurred in six dogs (12.2%); and a new MCT developed in 15 dogs (30.1%). Tumour location, histologic margin size and use of chemotherapy did not affect MST; increasing mitotic count (P = .001) and increasing tumour diameter (P = .024) were independently negatively prognostic. Six dogs that developed lymph node metastasis after surgery had worse MST (451 days) than 42 dogs that did not develop metastasis (1645 days); (P < .001). Our study suggests that dogs with local surgical control of clinical stage I histologically high Kiupel grade cutaneous MCT may have a long survival time; especially those with smaller tumours and a lower mitotic count. Our results suggest that evaluation of staging information and mitotic count may be equally helpful as histologic grading when making a prognosis; and highlight the importance of not relying on histologic grade alone when predicting survival for dogs with MCT.

中文翻译:

回顾性评估犬的手术切除,孤立的Kiupel高级别皮肤肥大细胞瘤的犬。

受临床阶段控制的特发性高度肥大细胞瘤(MCT)犬的已公布结果很少。评估了49例Kiupel高度,临床I期,皮肤MCT的狗的临床结局。中位生存时间(MST)为1046天;1年和2年生存率分别为79.3%和72.9%。在研究结束时,有24只狗死亡,有23只狗还活着(中位随访980天),有2只狗失去了随访。在20只已知死因的狗中,有14只被认为与MCT有关。9只狗(18.4%)出现局部肿瘤复发;6只犬(12.2%)发生了局部淋巴结转移;并在15只狗中开发了一种新的MCT(占30.1%)。肿瘤位置,组织学切缘大小和化学疗法的使用不影响MST;增加的有丝分裂计数(P= .001)和肿瘤直径增大(P = .024)独立地预后不良。六只在手术后发生淋巴结转移的狗(451天)比未转移的42只狗(1645天)的MST差;(P <.001)。我们的研究表明,对局部I期临床局部组织学控制且组织学水平高的Kiupel级皮肤MCT的犬,其生存时间可能较长;特别是那些肿瘤较小,有丝分裂数较少的患者。我们的结果表明,分期信息和有丝分裂计数的评估与进行预后时的组织学分级一样可能有用。并强调了在预测MCT狗的生存时不要仅依靠组织学分级的重要性。
更新日期:2020-01-14
down
wechat
bug